Find a Tender
complete
Official procurement procedure
Provision of WES Trio and Singleton Virtual Panel Analysis for Welsh Patients
Laboratory services
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust): "Provision of WES Trio and Singleton Virtual Panel Analysis for Welsh Patients". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Market Analytics
Derived from OCDS awards & bid statistics
Published history for NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
1Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 2 active published awards; 1 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Procedure methodNot published | Procurement categoryNot published | |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published24 Jun 2021, 15:04 BST | Last source update24 Jun 2021, 15:04 BST | Recurring procurementNot published |
ClassificationLaboratory services | ||
Delivery area | ||
OCIDocds-h6vhtk-02bfc8 | ||
What is being bought
In-line with All Wales Medical Genomic Service’s (AWMGS) commissioning model, AWMGS will procure from CeGaT whole exom sequencing (WES) for trio or singleton virtual panel analysis for patients where this testing cannot be accessed within the NHS E laboratory network. This genetic testing will ensure equity of access to genomic testing for Welsh patients and meet their need to seek a timely genetic diagnosis for their rare or inherited disease.
What changed
From the official release history
- Status changed to complete
24 Jun 2021, 15:04 BST - Official notice release published
24 Jun 2021, 15:04 BST - Buyer information updated
24 Jun 2021, 15:04 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedStatus not publishedPublished valueNot publishedNWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGS, for the supply of WES single and trio based testing from CeGAT. The contract is estimated to commence in July 2021, for a period of two years. The first year’s delivery will be capped at 175,000 GBP and reviewed to ensure that value for money is being achieved through the pick-up rate of pathogenic findings as a means of ensuring appropriate referrals and use of this bespoke service. The second year’s service will be capped at estimated 100,000 GBP assuming AWMGS are able to deliver in-house WES-based testing for Welsh patients within 2022/23 as currently planned.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
24 Jun 2021, 15:04 BST - Award active
Not published · Not published - Contract active
Signed 11 Jun 2021, 00:00 BST · £275,000
Commercial outcome and competition
Awards CeGaT GmbH Not published · Not published · active |
Contracts Contract £275,000 · signed 11 Jun 2021, 00:00 BST · active |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Contracting authority GB-FTS-6383Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleAll Wales Genomics Service (AWMGS) is commissioned by the Wealth Health Specialist Services Commission (WHSSC) to provide genetic testing for Welsh patients which is equitable to the provision NHS E makes available through the Rare and Inherited Disease Test Directory. NHS E patients can currently access a range of Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) tests for rare and inheritable diseases which the laboratory is unable to deliver in-house. In-house service developments are ongoing to enable the delivery of equivalent genetic tests but these will not go-live until 2022 – 24 (services will be introduced over a 18-24 month basis).
Where feasible, AWMGS commission genetic tests from within the NHS network for Welsh patients. NHS E genetic laboratories currently provide Welsh patients with access to a small number of trio WES-based tests, e.g. Exeter genetic laboratory provides and a larger number of phenotype driven singleton virtual panel tests. Importantly, WGS based testing is not available at all to AWMGS patients from NHS E laboratories due to the centralised model developed by Genetics England.
AWMGS will procure from CeGaT WES for trio or singleton virtual panel analysis for patients where this testing cannot be accessed within the NHS E laboratory network. For Single Exome Diagnostics, CeGaT will analyse a virtual panel of genes that are known to be associated with the patient’s phenotype. The virtual panel will be selected from a list of panels that have been curated by the NHS Genomic Medicine Service and are aligned to the NHSE Test Directory. These panels can be found at https://panelapp.genomicsengland.co.uk/
Targeted analysis of the ACMG genes is NOT requested for any samples received from AWMGS.
Should incidental or secondary findings be identified through routine analysis and not as part of a targeted analysis, these may reported to the referring clinician depending on the preference of the patient that will be indicated on the customised referral form that has been designed to meet the needs of the AWMGS service.
There is no alternative supplier within Europe providing an equivalent customised WES trio or singleton service to CeGAT which delivers against PanelApp green gene lists. Through procuring this specialist service from CeGAT AWMGS will ensure equity of access to genetic testing across NHS E and NHS W patient cohort in line with the commissioning model agreed with WHSSC. |